Accelerated Schedule of Hepatitis B Vaccination in Liver Transplant Candidates

1998 ◽  
Vol 30 (3) ◽  
pp. 797-799 ◽  
Author(s):  
B Kallinowski ◽  
C Benz ◽  
L Buchholz ◽  
W Stremmel
2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S775-S776
Author(s):  
Tilly Varughese ◽  
Michael Song ◽  
Joachim Sackey

Abstract Background Transplant candidates and recipients are at increased risk of infectious complications of vaccine-preventable diseases due to their longstanding immunosuppressive regimens. We assessed the rates of vaccination in our liver transplant patients at University Hospital (UH) in Newark, NJ. Methods Retrospective chart-review including patients > 18 years old who underwent liver transplantation at UH for a 3-year period from 01/01/2017 to 07/20/2020. Data collected included demographics, clinical outcomes, eligibility and receipt of vaccinations before and after transplantation, protection titers after administration of hepatitis vaccinations and presence of an ID outpatient consultation. We looked at the following receipt of vaccinations: Prevnar-13, Pneumovax-23, Influenza, TDaP, Shingrix, Varivax, Havrix and Engerix/Heplisav. Characteristics of study participants was analyzed using descriptive statistics and Chi-Square/Fisher’s Exact tests were used to test associations. Results 119 unique medical charts were reviewed and no patients were excluded. Of those patients who were eligible to receive Hepatitis A vaccination, only 44.8% were documented to receive vaccination and of those eligible to receive Hepatitis B vaccination, only 47.8% received it. Influenza vaccination pre-transplantation was 46% and 66.1% in post-transplant recipients. For the other vaccinations, during the pre-transplant period, 17.6 % of patients received Prevnar-13, 36.1% Pneumovax-23 and 20.2% TDaP and 26.1% received Shingrix. Patients who had ID consultation were significantly more likely to receive appropriate Hepatitis A and Hepatitis B vaccinations (p values 0.026 and 0.005). Conclusion We are not meeting national vaccination standards set by the American Society of Transplantation (AST) for optimal vaccination in this population. Our study can inform of possible solutions to increase vaccination rates in this population such as the simple addition of a smartphrase within EMR notes to remind providers to order appropriate vaccinations and eventually, a more long term solution of creation of a dedicated vaccination clinic and/or routine ID pre-transplant evaluations for all transplant candidates. Disclosures All Authors: No reported disclosures


1992 ◽  
Vol 37 (8) ◽  
pp. 1245-1249 ◽  
Author(s):  
David H. Van Thiel ◽  
Lobna El-Ashmawy ◽  
Kristin Love ◽  
Judith S. Gavaler ◽  
Thomas E. Starzl

2001 ◽  
Vol 13 (4) ◽  
pp. 363-367 ◽  
Author(s):  
Sigrid H. Engler ◽  
Peter W. Sauer ◽  
Markus Golling ◽  
Ernst A. Klar ◽  
Christine Benz ◽  
...  

2008 ◽  
Vol 12 (4) ◽  
pp. 306-309 ◽  
Author(s):  
Patricia R. Bonazzi ◽  
Telesforo Bacchella ◽  
Angela C. Freitas ◽  
Karina T. Osaki ◽  
Marta H. Lopes ◽  
...  

2013 ◽  
Vol 2 (2) ◽  
pp. 67-70
Author(s):  
Mukul Bhattarai ◽  
Pardeep Bansal ◽  
Michael Komar ◽  
Robert E Smith ◽  
Hitekshya Nepal

There are no randomized clinical trials on efficacy of Entecavir in Fulminant Hepatic Failure (FHF) due to Hepatitis B Virus (HBV). Definitive treatment of FHF remains Liver Transplant. However, availability of cadaveric donor organs is limited, and many of the patients with FHF may not be candidates for Liver Transplantation. There are only few case reports on beneficial effects of Entecavir in FHF due to HBV. We present 2 cases of FHF due to HBV. Both patients had severe liver cell damage among which one was immunocompromised. Transaminases were elevated up to 200 times the normal. Both were not transplant candidates, and were successfully treated with Entecavir resulting in significant clinical and transaminases improvement within 7 days of starting Entecavir. DOI: http://dx.doi.org/10.3126/jaim.v2i2.8780  Journal of Advances in Internal Medicine 2013;02(02):67-70


2005 ◽  
Vol 24 (2) ◽  
pp. S78
Author(s):  
W.Q. Foster ◽  
A. Murphy ◽  
D.J. Vega ◽  
W.M. Book

2018 ◽  
Vol 50 (10) ◽  
pp. 3681-3688 ◽  
Author(s):  
T.C.L. Wong ◽  
J.Y.Y. Fung ◽  
K.S.H. Chok ◽  
T.T. Cheung ◽  
A.C.Y. Chan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document